MedTrace Logo

Evaluation of Efficacy, Safety and Tolerability of VeraCept IUS

NCT03633799 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1620

Last updated 2025-08-22

Study results available
· View outcomes & findings →

Summary

To assess the contraceptive efficacy (prevention of pregnancy) of VeraCept

Conditions

  • Women at Risk for Pregnancy

Interventions

DRUG

VeraCept

VeraCept Intrauterine Contraceptive is a hormone free, low dose, copper-releasing birth control method

Sponsors & Collaborators

  • Syneos Health

    collaborator OTHER

  • Sebela Women's Health Inc.

    lead INDUSTRY

Principal Investigators

  • David Turok, MD, MPH · University of Utah

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-08-22
Primary Completion
2022-09-22
Completion
2027-09-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03633799 on ClinicalTrials.gov